# Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms

> **NCT05315856** · — · UNKNOWN · sponsor: **Korea University Guro Hospital** · enrollment: 120 (estimated)

## Conditions studied

- COVID-19 Vaccination
- Inflammation
- Vaccine Immune Response
- Vaccine Adverse Reaction

## Interventions

- **BIOLOGICAL:** either BNT162b2 or ChAdOx1 vaccine

## Key facts

- **NCT ID:** NCT05315856
- **Lead sponsor:** Korea University Guro Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05315856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05315856, "Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05315856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*